Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Announces Deals in South Korea for Clinical Assay Development, Neurometabolomic Research

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

Under the terms of the deal with Samsung, the Department of Laboratory Medicine & Genetics Research in Seoul, South Korea — part of the Center for Future Medicine at Samsung Medical Center — will use bio-analytical instruments from Agilent for the analysis of clinical samples and to develop novel clinical assays.

Instruments covered by the deal include the Agilent 6530 Accurate-Mass Q-TOF LC/MS platform and the 6430 Triple Quadrupole LC/MS system.

Sung-Hwa Hong, executive vice president of R&D at Samsung Medical Center, said in a statement that under a memorandum of understanding with Agilent, the partners will collaborate on the discovery and validation of protein biomarkers for applications in clinical trials; the development of methodology for applications involving hormones and vitamins; and the development of an assay for tumor markers for certain cancers and diseases.

Rudolf Grimm, Agilent's collaborations manager for South Korea and the South Asia Pacific region, added that researchers from Samsung and Agilent plan to collaborate on joint research projects to evaluate novel and "powerful" analytical technologies for future use in clinical environments.

Separately, Agilent said it has established a center for neurometabolomics R&D in Daegu, which will serve as the base for Agilent's collaborative work with the department of brain science at the Daegu Gyeongbuk Institute of Science and Technology (DGIST).

The deal is the firm's first collaboration in Asia for metabolomics research in brain science, it said.

"The goal of this center is not only to lead global collaborations in neurometabolomics but to foster and train researchers who will work in this area," Eun-Kyoung Kim, a professor in the department of brain science at DGIST, said in a statement. Kim will soon be appointed head of the Neurometabolomics Research and Training Center, Agilent said.

According to an MOU, Agilent will provide DGIST with early access to new technologies and software development. The center will be a reference site for Agilent customers in Asia who are interested in metabolomics and brain science.

Financial and other terms for the two deals were not disclosed.

The announcements follow an announcement on Wednesday from Agilent that it is partnering with with South Korea's Gachon University of Medicine and Science to use proteomics and glycoproteomics for biomarker discovery.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.